Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
ROSG's Cash to Debt is ranked higher than
94% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.07 vs. ROSG: No Debt )
ROSG' s 10-Year Cash to Debt Range
Min: 0.77   Max: No Debt
Current: No Debt

Equity to Asset 0.91
ROSG's Equity to Asset is ranked higher than
95% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. ROSG: 0.91 )
ROSG' s 10-Year Equity to Asset Range
Min: -0.27   Max: 0.95
Current: 0.91

-0.27
0.95
F-Score: 3
Z-Score: 4.41
M-Score: -3.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -3295.56
ROSG's Operating margin (%) is ranked lower than
55% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. ROSG: -3295.56 )
ROSG' s 10-Year Operating margin (%) Range
Min: -9864.67   Max: -3295.56
Current: -3295.56

-9864.67
-3295.56
Net-margin (%) -3184.44
ROSG's Net-margin (%) is ranked lower than
54% of the 174 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.31 vs. ROSG: -3184.44 )
ROSG' s 10-Year Net-margin (%) Range
Min: -11003.33   Max: -3184.44
Current: -3184.44

-11003.33
-3184.44
ROE (%) -54.57
ROSG's ROE (%) is ranked higher than
52% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. ROSG: -54.57 )
ROSG' s 10-Year ROE (%) Range
Min: -241.23   Max: -33.84
Current: -54.57

-241.23
-33.84
ROA (%) -49.83
ROSG's ROA (%) is ranked higher than
52% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. ROSG: -49.83 )
ROSG' s 10-Year ROA (%) Range
Min: -432   Max: -32.15
Current: -49.83

-432
-32.15
ROC (Joel Greenblatt) (%) -1527.12
ROSG's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. ROSG: -1527.12 )
ROSG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1527.12   Max: -838.2
Current: -1527.12

-1527.12
-838.2
Revenue Growth (%) -65.70
ROSG's Revenue Growth (%) is ranked higher than
52% of the 148 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. ROSG: -65.70 )
ROSG' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -57.7
Current: -65.7

EBITDA Growth (%) -68.90
ROSG's EBITDA Growth (%) is ranked lower than
53% of the 125 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.50 vs. ROSG: -68.90 )
ROSG' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: -4.6
Current: -68.9

EPS Growth (%) -68.90
ROSG's EPS Growth (%) is ranked lower than
53% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.60 vs. ROSG: -68.90 )
ROSG' s 10-Year EPS Growth (%) Range
Min: -68.9   Max: 45.9
Current: -68.9

-68.9
45.9
» ROSG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with ROSG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.80
ROSG's P/B is ranked higher than
92% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.83 vs. ROSG: 1.80 )
ROSG' s 10-Year P/B Range
Min: 0.73   Max: 4.84
Current: 1.8

0.73
4.84
P/S 92.59
ROSG's P/S is ranked higher than
55% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.41 vs. ROSG: 92.59 )
ROSG' s 10-Year P/S Range
Min: 3.33   Max: 209.09
Current: 92.59

3.33
209.09
EV-to-EBIT -1.22
ROSG's EV-to-EBIT is ranked lower than
60% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ROSG: -1.22 )
ROSG' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -1.22

Current Ratio 12.90
ROSG's Current Ratio is ranked higher than
94% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. ROSG: 12.90 )
ROSG' s 10-Year Current Ratio Range
Min: 0.65   Max: 25.08
Current: 12.9

0.65
25.08
Quick Ratio 12.90
ROSG's Quick Ratio is ranked higher than
94% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.48 vs. ROSG: 12.90 )
ROSG' s 10-Year Quick Ratio Range
Min: 0.65   Max: 25.08
Current: 12.9

0.65
25.08

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.80
ROSG's Price/Net Cash is ranked higher than
99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ROSG: 1.80 )
ROSG' s 10-Year Price/Net Cash Range
Min: 1.31   Max: 7.58
Current: 1.8

1.31
7.58
Price/Net Current Asset Value 1.80
ROSG's Price/Net Current Asset Value is ranked higher than
99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. ROSG: 1.80 )
ROSG' s 10-Year Price/Net Current Asset Value Range
Min: 1.31   Max: 7
Current: 1.8

1.31
7
Price/Tangible Book 1.70
ROSG's Price/Tangible Book is ranked higher than
95% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.75 vs. ROSG: 1.70 )
ROSG' s 10-Year Price/Tangible Book Range
Min: 1.02   Max: 3.68
Current: 1.7

1.02
3.68
Price/Median PS Value 1.50
ROSG's Price/Median PS Value is ranked higher than
70% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. ROSG: 1.50 )
ROSG' s 10-Year Price/Median PS Value Range
Min: 0.2   Max: 2.37
Current: 1.5

0.2
2.37
Earnings Yield (Greenblatt) 2465.60
ROSG's Earnings Yield (Greenblatt) is ranked higher than
98% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. ROSG: 2465.60 )
ROSG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 5877
Current: 2465.6

0
5877
Forward Rate of Return (Yacktman) -616.18
ROSG's Forward Rate of Return (Yacktman) is ranked lower than
54% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.81 vs. ROSG: -616.18 )
ROSG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -616.18

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:RQ1.Germany
Rosetta Genomics, Ltd., develops diagnostic tests and therapeutic tools. Its product portfolio comprises of tests such as miRview mets2/mets, miRview squamous, miRview meso and miRview kidney.
» More Articles for NAS:ROSG

Headlines

Articles On GuruFocus.com
Rosetta Genomics Reports Second Quarter Financial Results, Provides Business Update Sep 08 2009 
Rosetta Genomics Announces Exclusive Distribution Agreement With Teva Pharmaceutical Industries Ltd. Jan 08 2009 
Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $ Dec 08 2008 

More From Other Websites
Nasdaq stocks posting largest volume increases Jul 31 2014
Rosetta Genomics Announces Agreement With Global Pharmaceutical Company to Advance Efforts in... Jul 31 2014
Rosetta Genomics Announces Agreement With Global Pharmaceutical Company to Advance Efforts in... Jul 31 2014
Rosetta Genomics Announces Next-Generation Sequencing Research Collaboration With Weizmann Institute... Jul 29 2014
Rosetta Genomics Announces Next-Generation Sequencing Research Collaboration With Weizmann Institute... Jul 29 2014
Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test Jul 22 2014
Rosetta Genomics Receives Final New York State Approval for Rosetta Kidney Cancer Test Jul 22 2014
Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer Jul 10 2014
Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Treatment of Ovarian Cancer Jul 10 2014
ROSG: Collaboration Accelerates Product Development and Represents New Avenue for Revenue Growth Jun 27 2014
Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of... Jun 26 2014
UPDATE: Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of... Jun 09 2014
Rosetta, Moffitt enter into agreement for thyroid neoplasia assay Jun 09 2014
Rosetta Genomics and Moffitt Cancer Center Enter Into Agreement to Advance Development of... Jun 09 2014
UPDATE: Barrington Research Initiates Coverage On Rosetta Genomics Ltd. On Good Market Position Jun 04 2014
ROSETTA GENOMICS LTD. Financials Apr 05 2014
Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay Apr 04 2014
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-Based... Apr 02 2014
ROSG: Three Platforms Will Drive Revenue Growth in 2014 and Beyond Apr 02 2014
Rosetta Genomics Reports 2013 Financial Results Mar 31 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide